Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from Bright Minds Biosciences ( (TSE:DRUG) ) is now available.
Bright Minds Biosciences has appointed Dr. Stephen Collins as its new Chief Medical Officer, succeeding Dr. Mark A. Smith, who will remain as an advisor. Dr. Collins brings significant expertise in CNS drug development, which aligns with the company’s mission to advance treatments for epilepsy and other CNS disorders. This strategic appointment comes as Bright Minds progresses with its Phase 2 clinical trial of BMB-101, aiming to improve therapeutic outcomes for rare epilepsies.
More about Bright Minds Biosciences
Bright Minds Biosciences is a pioneering company in the biotechnology industry, focusing on the development of highly selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and other CNS disorders.
YTD Price Performance: -4.41%
Average Trading Volume: 17,446
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$407.5M
For an in-depth examination of DRUG stock, go to TipRanks’ Stock Analysis page.
